Jci_page_head_homepage_01 Jci_page_head_homepage_02
Yasunobu Miyake, Kenichi Asano, Hitomi Kaise, Miho Uemura, Manabu Nakayama, Masato Tanaka
Published in Volume 117, Issue 8
J Clin Invest. 2007; 117(8):2268–2278 doi:10.1172/JCI31990
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 4
Generation of CD169-DTR mice.

(A) Schematic diagram of the CD169-DTR targeting construct. Exons of the CD169 gene are indicated by solid boxes. Human DTR (hDTR) cDNA, the loxP-franked neomycin resistant gene (Neo), and the thymidine kinase gene (TK) are indicated by open boxes. The probe used for Southern blot analysis is indicated as a solid line together with the predicted hybridizing fragments. (B) Genomic Southern blot analysis of wild-type (+/+) and CD169-DTR (+/CD169DTR) mice using a Bgl II digest in combination with the indicated probe. (C) Depletion of macrophages in the MZ by DT administration in CD169-DTR mice. The indicated amount of DT was intraperitoneally injected into wild-type (+/+) or CD169-DTR (+/CD169DTR) mice. Spleens were obtained from these mice 48 hours later. Spleen sections were immunostained with CD11b, ER-TR9, CD169, and CD11c for red pulp macrophages, MZM, MMM, and DCs, respectively. (D) We intraperitoneally injected 10 μg/kg of DT into wild-type mice (+/+) and CD169-DTR (+/CD169DTR) mice. Spleens were obtained from these mice on the indicated days after DT administration and immunostained with ER-TR9 and CD169. Original magnification, ×100 (C and D).